Arcadia Biosciences Announces Fourth-Quarter and Full-Year 2017 Financial Results and Business
Highlights
-- Revenues Up, Losses Down, Commercialization Plans Underway for Consumer-Driven Health and
Nutrition Ingredient Traits --
Arcadia Biosciences, Inc. (Nasdaq: RKDA), a consumer-driven, agricultural food ingredient company, today released its financial
and business results for the fourth quarter and full year of 2017.
“2017 was a pivotal year for Arcadia as we sharpened our focus on the commercialization of our non-GM quality and nutrition
ingredient traits for the $200B global wheat flour market and demonstrated steady advancement towards the commercialization of our
high-value agricultural productivity traits in Argentina and Asia,” said Raj Ketkar, president and CEO. “We achieved notable
reductions in our operating loss for the fourth quarter and full year, driven primarily by continued cost containment and the cost
efficiencies brought about through focus on a select group of products.
“With the organization in place and commercial launch plans underway in 2018, yesterday we secured $10 million in private equity
financing that meaningfully fortifies our cash resources and allows us to effectively execute our health and nutrition growth
strategy,” Ketkar said. “This additional financing will accelerate our commercialization activities and demonstrates our commitment
to maximizing value for food companies, consumers, growers and our shareholders.”
2017 Operating and Financial Highlights
- Non-GM Wheat Trait Portfolio. Arcadia advanced its non-GM wheat trait
portfolio significantly in 2017 by developing new lines of high fiber Resistant Starch wheat with industry-leading levels of
amylose, and identified the phenotype for Reduced Gluten wheat. The company in-licensed CRISPR-Cas9 gene editing technology and
began integrating the technology to accelerate current development programs.
- Strategy. Arcadia validated its strategy to capture value further down
the food value chain and built the foundation of a sales and marketing team focused on high-value branded ingredients.
- GoodWheat™ Brand. As a result of the company’s strategy validation to
give consumer packaged goods companies an opportunity to differentiate their brands, Arcadia developed a unique, consumer-facing
ingredient brand, GoodWheat™.
- HB4 Drought Tolerant Soybeans. Arcadia and its Verdeca joint venture
partner, Bioceres, advanced HB4 drought tolerant soybeans with the FDA’s regulatory approval of the trait for human food and
animal feed. Positive results are anticipated for the 2017 efficacy field trials in South America. Additionally, Arcadia and its
partner Mahyco are working to restructure the licenses for our abiotic stress traits for accelerated deregulation.
- Financial performance. Overall revenues were up for the year and
operating expenses were down, resulting in a significant reduction in loss. Operating expenses were down by more than 25 percent
from the prior year’s fourth quarter and by more than 15 percent from the prior year, with net loss and net loss attributable to
common stockholders down by 20 percent from the prior year. Toward the end of 2017, Arcadia extinguished a costly debt
instrument, saving a total of $2 million in cash interest payments over the remaining term of the loan.
2018 Strategic Outlook
- Executing branded ingredients strategy. In 2018, Arcadia will launch its
commercialization plan to become a consumer-driven, branded food ingredient company providing value-added traits to the health
and nutrition foods industries.
- Building commercialization capabilities. Arcadia hired Sarah Reiter as
chief commercial officer, with over 20 years of experience in agriculture, to help us migrate forward in the ag-food supply
chain, expand our nutrition and health ingredients capabilities and strengthen commercial relationships with consumer food
companies.
|
Arcadia Biosciences, Inc.
Financial Snapshot
(Unaudited)
($ in thousands)
|
|
|
|
|
|
Three Months Ended December 31 |
|
Year Ended December 31 |
|
2017 |
|
|
2016 |
|
|
% Favorable/
(Unfavorable)
|
|
2017 |
|
|
2016 |
|
|
% Favorable/
(Unfavorable)
|
| Total Revenues |
1,428 |
|
|
540 |
|
|
165 |
% |
|
4,026 |
|
|
3,188 |
|
|
26 |
% |
| Total Operating Expenses |
4,428 |
|
|
6,011 |
|
|
26 |
% |
|
18,341 |
|
|
21,808 |
|
|
16 |
% |
| Loss From Operations |
(3,000 |
) |
|
(5,471 |
) |
|
45 |
% |
|
(14,315 |
) |
|
(18,620 |
) |
|
23 |
% |
| Net Loss Attributable to Common Stockholders |
(2,960 |
) |
|
(5,708 |
) |
|
48 |
% |
|
(15,707 |
) |
|
(19,624 |
) |
|
20 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
In the fourth quarter of 2017, revenues were $1.4 million, compared to revenues of $540,000 in the fourth quarter of 2016. For
annual 2017, overall revenues increased to $4.0 million compared to $3.2 million during the same period of 2016. The
quarter-over-quarter and annual results were primarily impacted by previously deferred upfront license fees recognized as several
agreements were discontinued in the fourth quarter of 2017, as well as delays identified in the fourth quarter of 2016 to the
estimated commercial launch dates within the portfolio of license agreements.
Operating Expenses
In the fourth quarter of 2017, operating expenses were $4.4 million, compared to $6.0 million in the fourth quarter of 2016. For
annual 2017, operating expenses were $18.3 million, compared to $21.8 million during the same period in 2016. Annual research and
development (R&D) spending decreased by $1.3 million in 2017 and general and administrative (SG&A) decreased by $1.6
million. Both expense categories had decreases driven primarily by lower salaries and benefits, mainly the result of workforce
reductions made during the latter part of 2016. Cost of product revenues decreased by $612,000 as 2016 included a write-down of
inventory and none was recorded in 2017.
Net Loss Attributable to Common Stockholders
Net loss attributable to common stockholders for the fourth quarter of 2017 was $3.0 million, or a loss of $1.39 per share, a 48
percent improvement from the $5.7 million loss in the fourth quarter of 2016. Net loss attributable to common stockholders for the
year was $15.7 million, or a loss of $7.28 per share, a 20 percent improvement from the $19.6 million loss in 2016.
The net loss attributable to common stockholders in the fourth quarter of 2016 included interest expense on the term loan that
was paid off in the third quarter of 2017. The annual loss for 2017 includes a non-recurring loss on extinguishment of debt in the
amount of $900,000, as well as interest expense through the date of payoff.
Conference Call and Webcast
The company has scheduled a conference call for 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss fourth-quarter and annual
results and key strategic achievements.
Interested participants can join the conference call using the following numbers:
| U.S. Toll-Free Dial-In: |
|
+1-844-243-4690
|
| International Dial-In: |
|
+1-225-283-0138 |
| Passcode: |
|
7664338 |
A live webcast of the conference call will be available on the “Investors” section of the Arcadia’s website at www.arcadiabio.com. Following completion of the call, a recorded replay will be available on the company’s
investor website.
Safe Harbor Statement
“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release and the accompanying
conference call contain forward-looking statements about the company and its products, including statements relating to components
of the company’s long-term financial success and ongoing plans; the company’s traits, commercial products, and collaborations; and
the company’s ability to manage the regulatory processes for its traits and commercial products. Forward-looking statements are
subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be
considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company’s and
its partners’ ability to develop commercial products incorporating its traits and to complete the regulatory review process for
such products; the company’s compliance with laws and regulations that impact the company’s business, and changes to such laws and
regulations; and the company’s future capital requirements and ability to satisfy its capital needs. Further information regarding
these and other factors that could affect the company’s financial results is included in filings the company makes with the
Securities and Exchange Commission from time to time, including the section entitled “Risk Factors” in the company’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2017 and additional information that will be set forth in its Form 10-K for
the year ended December 31, 2017. These documents are or will be available on the SEC Filings section of the Investor Relations
pages of the company’s website at www.arcadiabio.com. All information provided in this release and in the attachments is as of the date hereof,
and Arcadia Biosciences, Inc. undertakes no duty to update this information.
About Arcadia Biosciences, Inc.
Based in Davis, Calif., Arcadia Biosciences (Nasdaq: RKDA) develops agricultural products that create added value for farmers,
enhance human health and improve the environmental sustainability of agriculture. Arcadia’s nutrition traits and products are aimed
at creating healthier ingredients and whole foods with lower production costs. Arcadia’s agronomic performance traits are aimed at
making agricultural production more economically efficient and environmentally sound. For more information, visit www.arcadiabio.com
|
Arcadia Biosciences, Inc.
Consolidated Balance Sheets
(Unaudited)
(In thousands, except share data)
|
|
|
|
|
|
|
As of December 31, |
|
|
2017 |
|
|
2016 |
|
| Assets |
|
|
|
|
|
|
|
| Current assets: |
|
|
|
|
|
|
|
| Cash and cash equivalents |
$ |
9,125 |
|
|
$ |
2,013 |
|
| Short-term investments |
|
3,898 |
|
|
|
48,547 |
|
| Accounts receivable |
|
1,231 |
|
|
|
349 |
|
| Unbilled revenue |
|
4 |
|
|
|
184 |
|
| Inventories — current |
|
229 |
|
|
|
252 |
|
| Prepaid expenses and other current assets |
|
560 |
|
|
|
877 |
|
| Total current assets |
|
15,047 |
|
|
|
52,222 |
|
| Property and equipment, net |
|
299 |
|
|
|
508 |
|
| Inventories — noncurrent |
|
1,168 |
|
|
|
1,327 |
|
| Long-term investments |
|
— |
|
|
|
2,498 |
|
| Other noncurrent assets |
|
56 |
|
|
|
19 |
|
| Total assets |
$ |
16,570 |
|
|
$ |
56,574 |
|
| Liabilities and stockholders’ equity |
|
|
|
|
|
|
|
| Current liabilities: |
|
|
|
|
|
|
|
| Accounts payable and accrued expenses |
$ |
2,496 |
|
|
$ |
2,359 |
|
| Amounts due to related parties |
|
29 |
|
|
|
30 |
|
| Unearned revenue — current |
|
1,000 |
|
|
|
740 |
|
| Total current liabilities |
|
3,525 |
|
|
|
3,129 |
|
| Notes payable |
|
— |
|
|
|
25,127 |
|
| Unearned revenue — noncurrent |
|
2,038 |
|
|
|
3,120 |
|
| Other noncurrent liabilities |
|
3,000 |
|
|
|
3,000 |
|
| Total liabilities |
|
8,563 |
|
|
|
34,376 |
|
| Stockholders’ equity: |
|
|
|
|
|
|
|
|
Common stock, $0.001 par value—150,000,000 and 400,000 shares
authorized as of December 31, 2017 and December 31, 2016; 2,134,154
and 2,224,384 shares issued and outstanding as of December 31, 2017
and December 31, 2016, respectively
|
|
42 |
|
|
|
44 |
|
| Additional paid-in capital |
|
175,223 |
|
|
|
173,723 |
|
| Accumulated deficit |
|
(167,257 |
) |
|
|
(151,550 |
) |
| Accumulated other comprehensive loss |
|
(1 |
) |
|
|
(19 |
) |
| Total stockholders’ equity |
|
8,007 |
|
|
|
22,198 |
|
| Total liabilities and stockholders’ equity |
$ |
16,570 |
|
|
$ |
56,574 |
|
|
|
|
|
|
|
|
|
|
Arcadia Biosciences, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(In thousands, except share and per share data)
|
|
|
|
|
|
|
Year Ended December 31, |
|
|
|
2017 |
|
|
2016 |
|
| Revenues: |
|
|
|
|
|
|
|
|
| Product |
|
$ |
514 |
|
|
$ |
669 |
|
| License |
|
|
1,470 |
|
|
|
144 |
|
| Contract research and government grants |
|
|
2,042 |
|
|
|
2,375 |
|
| Total revenues |
|
|
4,026 |
|
|
|
3,188 |
|
| Operating expenses: |
|
|
|
|
|
|
|
|
| Cost of product revenues |
|
|
283 |
|
|
|
895 |
|
| Research and development |
|
|
7,407 |
|
|
|
8,663 |
|
| Selling, general and administrative |
|
|
10,651 |
|
|
|
12,250 |
|
| Total operating expenses |
|
|
18,341 |
|
|
|
21,808 |
|
| Loss from operations |
|
|
(14,315 |
) |
|
|
(18,620 |
) |
| Interest expense |
|
|
(747 |
) |
|
|
(1,319 |
) |
| Other income, net |
|
|
281 |
|
|
|
340 |
|
| Loss on extinguishment of debt |
|
|
(900 |
) |
|
|
— |
|
| Net loss before income taxes |
|
|
(15,681 |
) |
|
|
(19,599 |
) |
| Income tax provision |
|
|
(26 |
) |
|
|
(25 |
) |
| Net loss attributable to common stockholders |
|
$ |
(15,707 |
) |
|
$ |
(19,624 |
) |
| Net loss per share attributable to common stockholders: |
|
|
|
|
|
|
|
|
| Basic and diluted |
|
$ |
(7.28 |
) |
|
$ |
(8.85 |
) |
|
Weighted-average number of shares used in per share
calculations:
|
|
|
|
|
|
|
|
|
| Basic and diluted |
|
|
2,156,201 |
|
|
|
2,218,341 |
|
| Other comprehensive income, net of tax |
|
|
|
|
|
|
|
|
| Unrealized gains on available-for-sale securities |
|
|
18 |
|
|
|
96 |
|
| Other comprehensive income |
|
|
18 |
|
|
|
96 |
|
| Comprehensive loss attributable to common stockholders |
|
$ |
(15,689 |
) |
|
$ |
(19,528 |
) |
|
|
|
|
|
|
|
|
|
|
Arcadia Biosciences, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
(In thousands)
|
|
|
|
|
|
|
Year Ended December 31, |
|
|
|
2017 |
|
|
2016 |
|
| CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|
|
|
|
|
| Net loss |
|
$ |
(15,707 |
) |
|
$ |
(19,624 |
) |
| Adjustments to reconcile net loss to cash used in operating activities: |
|
|
|
|
|
|
|
|
| Depreciation and amortization |
|
|
279 |
|
|
|
304 |
|
| (Gain) Loss on disposal of equipment |
|
|
(1 |
) |
|
|
4 |
|
| Net amortization of investment premium and discount |
|
|
(89 |
) |
|
|
140 |
|
| Loss on sale of investments |
|
|
2 |
|
|
|
— |
|
| Stock-based compensation |
|
|
1,474 |
|
|
|
1,059 |
|
| Accretion of debt discount |
|
|
98 |
|
|
|
198 |
|
| Loss on extinguishment of debt |
|
|
900 |
|
|
|
— |
|
| Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
| Accounts receivable |
|
|
(882 |
) |
|
|
357 |
|
| Unbilled revenue |
|
|
179 |
|
|
|
(102 |
) |
| Inventories |
|
|
183 |
|
|
|
582 |
|
| Prepaid expenses and other current assets |
|
|
324 |
|
|
|
(185 |
) |
| Other noncurrent assets |
|
|
11 |
|
|
|
5 |
|
| Accounts payable and accrued expenses |
|
|
87 |
|
|
|
(19 |
) |
| Amounts due to related parties |
|
|
(1 |
) |
|
|
11 |
|
| Unearned revenue |
|
|
(822 |
) |
|
|
215 |
|
| Net cash used in operating activities |
|
|
(13,965 |
) |
|
|
(17,055 |
) |
| CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
|
|
|
|
|
|
| Proceeds from sale of property and equipment |
|
|
4 |
|
|
|
— |
|
| Purchases of property and equipment |
|
|
(79 |
) |
|
|
(231 |
) |
| Purchases of investments |
|
|
(19,405 |
) |
|
|
(41,385 |
) |
| Proceeds from sales and maturities of investments |
|
|
66,658 |
|
|
|
36,315 |
|
| Net cash provided by (used in) investing activities |
|
|
47,178 |
|
|
|
(5,301 |
) |
| CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
|
|
|
|
|
|
| Payments of debt issuance costs |
|
|
— |
|
|
|
(46 |
) |
| Payments of debt extinguishment costs |
|
|
(1,125 |
) |
|
|
— |
|
| Payments on notes payable |
|
|
(25,000 |
) |
|
|
— |
|
| Proceeds from exercise of stock options and purchases through ESPP |
|
|
24 |
|
|
|
442 |
|
| Net cash (used in) provided by financing activities |
|
|
(26,101 |
) |
|
|
396 |
|
| Net increase (decrease) in cash and cash equivalents |
|
|
7,112 |
|
|
|
(21,960 |
) |
| Cash and cash equivalents — beginning of period |
|
|
2,013 |
|
|
|
23,973 |
|
| Cash and cash equivalents — end of period |
|
$ |
9,125 |
|
|
$ |
2,013 |
|
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: |
|
|
|
|
|
|
|
|
| Cash paid for interest |
|
$ |
746 |
|
|
$ |
1,033 |
|
| Cash paid for income taxes |
|
$ |
2 |
|
|
$ |
29 |
|
| NONCASH INVESTING AND FINANCING ACTIVITIES: |
|
|
|
|
|
|
|
|
| Exchange of membership interest in unconsolidated entity for common
stock |
|
$ |
2 |
|
|
$ |
— |
|
| Proceeds from sale of fixed assets included in prepaid expenses and other
current assets |
|
$ |
7 |
|
|
$ |
— |
|
| Deferred financing costs in accounts payable and accrued expenses |
|
$ |
50 |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
Arcadia Biosciences, Inc.
Jeff Bergau, +1-312-217-0419
jeff.bergau@arcadiabio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180320006506/en/